38
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more than 320 million people worldwide, which is more than HIV, tuberculosis (TB) and malaria combined. Elimination of HBV and HCV will, therefore, produce substantial public health and economic benefits and, most importantly, the prevention of 1.2 million deaths per year. In 2016, member states of the World Health Assembly unanimously adopted a resolution declaring that viral hepatitis should be eliminated by 2030. Currently, few countries have elimination programmes in place and even though the tools to achieve elimination are available, the right resources, commitments and allocations are lacking. During the fifth International Viral Hepatitis Elimination Meeting (IVHEM), 7–8 December 2018, Amsterdam, the Netherlands, an expert panel of clinicians, virologists and public health specialists discussed the current status of viral hepatitis elimination programmes across multiple countries, challenges in achieving elimination and the core indicators for monitoring progress, approaches that have failed and successful elimination plans.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: found

          Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

          The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of-and expansion on-the 2014 analysis, which reported 80 million (95% CI 64-103) viraemic infections in 2013.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

            Background With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2013. Methods We estimated mortality using natural history models for acute hepatitis infections and GBD’s cause-of-death ensemble model for cirrhosis and liver cancer. We used meta-regression to estimate total cirrhosis and total liver cancer prevalence, as well as the proportion of cirrhosis and liver cancer attributable to each cause. We then estimated cause-specific prevalence as the product of the total prevalence and the proportion attributable to a specific cause. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs). Findings Between 1990 and 2013, global viral hepatitis deaths increased from 0·89 million (95% uncertainty interval [UI] 0·86–0·94) to 1·45 million (1·38–1·54); YLLs from 31·0 million (29·6–32·6) to 41·6 million (39·1–44·7); YLDs from 0·65 million (0·45–0·89) to 0·87 million (0·61–1·18); and DALYs from 31·7 million (30·2–33·3) to 42·5 million (39·9–45·6). In 2013, viral hepatitis was the seventh (95% UI seventh to eighth) leading cause of death worldwide, compared with tenth (tenth to 12th) in 1990. Interpretation Viral hepatitis is a leading cause of death and disability worldwide. Unlike most communicable diseases, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. The enormous health loss attributable to viral hepatitis, and the availability of effective vaccines and treatments, suggests an important opportunity to improve public health. Funding Bill & Melinda Gates Foundation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy

              Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. The incidence of HCV among Dutch human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) has been high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections.
                Bookmark

                Author and article information

                Journal
                J Virus Erad
                J Virus Erad
                JOURNAL OF VIRUS ERADICATION
                Journal of Virus Eradication
                Mediscript Ltd
                2055-6640
                2055-6659
                January 2019
                1 January 2019
                : 5
                : 1
                : 60-66
                Affiliations
                [ 1 ] Department of Viroscience, Erasmus Medical Center , Erasmus University , Rotterdam, the Netherlands
                [ 2 ] Virology Education , Utrecht, the Netherlands
                [ 3 ] Amsterdam UMC location Meibergdreef , Amsterdam, the Netherlands
                [ 4 ] Department of Pediatrics , Ain Shams University , Cairo, Egypt
                [ 5 ] Division of Gastroenterology , Department of Medicine , Landspitali University Hospital , Reykjavik, Iceland
                [ 6 ] Department of Hygiene , Epidemiology and Medical Statistics , Medical School , National and Kapodistrian University of Athens , Greece
                [ 7 ] Gastroenterology Section , VA Long Beach Healthcare System , Long Beach, CA, USA
                [ 8 ] National Center for Disease Control and Public Health , Tbilisi, Georgia
                [ 9 ] Kigali University , Kigali, Rwanda
                [ 10 ] Inserm, Université Paris Diderot , UFR de Médicine-site Bichart , Paris, France
                [ 11 ] World Hepatitis Alliance , London, UK
                [ 12 ] Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health , University of Toronto , Toronto, Canada
                [ 13 ] Disease Elimination Program , Burnet Institute , Melbourne, Australia
                [ 14 ] National Center for HIV , Viral Hepatitis , STD, and TB, CDC , Atlanta, GA, USA
                [ 15 ] Task Force for Global Health, Decatur , Atlanta, GA, USA
                Author notes
                Corresponding author: Stephanie Popping, Viroscience department , Erasmus MC , Postbus 2040, 3000CA, Rotterdam, the Netherlands Email: s.popping@ 123456erasmusmc.nl
                Article
                10.1016/S2055-6640(20)30281-8
                6362901
                30800429
                49312803-f264-4258-b1c6-101a5f7c16e6
                © 2019 The Authors.  Journal of Virus Eradication published by Mediscript Ltd

                This is an open access article published under the terms of a Creative Commons License.

                History
                Categories
                Conference Report

                hepatitis c virus,elimination,world health organization,hepatitis b virus,viral hepatitis

                Comments

                Comment on this article